Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc.

Bristol-Myers Squibb Company BMY announced that yesterday it successfully completed the tender offer by Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin Pharmaceuticals, Inc. AMLN (“Amylin”) at a purchase price of $31.00 per share. As of the expiration of the offer yesterday, 140,550,153 shares of common stock of Amylin were validly tendered and not withdrawn in the tender offer. As part of the successful completion of the tender offer, Bristol-Myers Squibb exercised its right granted under the merger agreement with Amylin pursuant to which the tender offer was made to purchase additional shares from Amylin which would allow Bristol-Myers Squibb to complete the merger without stockholder approval.